Stockmarket

Biogen's Samsung Bioepis Stake Sale a Positive, Analysts Say



© Reuters

By Sam Boughedda

Investing.com — Biogen Inc (NASDAQ:) shares rose 0.2% on Friday, a day after the biotech said it would sell a stake in its Bioepis joint venture.

The company said Thursday night it was selling the stake to Samsung Biologics for up to $2.3 billion.

Biogen has a 49.9% share in the joint venture. It initially invested in a 15% stake in Samsung Bioepis when it was established in 2012, with the company having the right to purchase up to 49.9%, which it exercised in June 2018.

Biogen is currently facing uncertainties surrounding its Alzheimer’s drug Aduhelm. Analysts at Needham and JPMorgan view the sale of its Bioepis stake favorably.  

Needham analyst, Ami Fadia, told investors in a note they “believe the sale will give management the capital to pursue strategic alternatives including business development while divesting its stake in a business where it did not have any long term prospects for a reasonable return. 

“With uncertainty around Aduhelm, the company is under pressure to explore alternatives growth opportunities, and we see this as a positive step in that direction.”

Fadia reiterated a buy rating on Biogen and a $292 price target.

In addition to Needham, JPMorgan’s Cory Kasimov said in a client note that the deal bolsters Biogen’s balance sheet and provides added flexibility. However, the analyst warned that the bigger focus is still on the Alzheimer’s outlook, with the “obvious challenges” facing Aduhelm.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.